Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [929]

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR...

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )

ESMO 2025: Latest in EGFR mutant NSCLC

Dr Alfredo Addeo, Prof Nicolas Girard, Dr Anna Minchom and Prof Pascale Tomasini

ESMO 2025: Latest in EGFR mutant NSCLC ( Dr Alfredo Addeo, Prof Nicolas Girard, Dr Anna Minchom and Prof Pascale Tomasini )

MCED blood test demonstrates high specificity, strong predictive value, and...

Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection ( Dr Nima Nabavizadeh - Oregon Health & Science University, Portland, USA )

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in...

Prof Martin Schuler - Essen University Hospital, Essen, Germany

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC...

Dr Geoffrey Liu - University of Toronto, Toronto, Canada

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib ( Dr Geoffrey Liu - University of Toronto, Toronto, Canada )

NSCLC brain metastases: TTFields after SRS delays intracranial progression...

Dr Vinai Gondi - Northwestern Medicine West Region and Proton Center, Illinois...

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL ( Dr Vinai Gondi - Northwestern Medicine West Region and Proton Center, Illinois, USA )

Supportive care intervention improves function and reduces fatigue in older...

Dr Carolyn Presley - The Ohio State University, Columbus, USA

Supportive care intervention improves function and reduces fatigue in older lung cancer patients ( Dr Carolyn Presley - The Ohio State University, Columbus, USA )

Improving efficacy and toxicity reporting - and treatment insights from an...

Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient ( Dr Ross Camidge - University of Colorado School of Medicine, Aurora, Colorado )

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC...

Dr Matthew McMillan - Memorial Sloan-Kettering Cancer Center, New York, USA

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression ( Dr Matthew McMillan - Memorial Sloan-Kettering Cancer Center, New York, USA )

WCLC 2025: Latest in EGFR positive NSCLC

Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil...

WCLC 2025: Latest in EGFR positive NSCLC ( Prof Enriqueta Felip, Dr Antonio Passaro, Dr Alex Spira and Prof Ignacio Gil-Bazo )

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

The hidden biology of addiction and cancer

Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA

The hidden biology of addiction and cancer ( Prof Raphael Cuomo - UC San Diego School of Medicine, San Diego, USA )

More from ecancer